So far, there have been 2 encouraging clinical trials using the CD30 antibody and CD30-chimeric antigen receptor-engineered T (CART) cells in the treatment of NKTCL (NCT02588651 and NCT03049449, respectively). Here, TNFRSF8 is linked to extranodal nasal NK/T cell lymphoma.